Discussion About Diagnosis and Treatment Regularity of Infectious Lung Disease Epidemic and New Explanation of Lianhua Qingwen Formula

JIA Zhenhua

doi:10.13422/j.cnki.syfjx.20241247

您当前的位置：

首页 >

文章列表页 >

Discussion About Diagnosis and Treatment Regularity of Infectious Lung Disease Epidemic and New Explanation of Lianhua Qingwen Formula

更新时间：2024-07-31

- Discussion About Diagnosis and Treatment Regularity of Infectious Lung Disease Epidemic and New Explanation of Lianhua Qingwen Formula
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 30, Issue 17, Pages: 203-210(2024)
- 作者机构：
  
  络病理论创新转化全国重点实验室，河北省中西医结合医药研究院，石家庄 050035
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20241247
  CLC： R22;R28;R24
- Published：05 September 2024，
  
  Published Online：06 June 2024，
  
  Received：01 June 2024，
- 稿件说明：
扫描看全文
贾振华.肺疫证治规律探讨与连花清瘟组方新解[J].中国实验方剂学杂志,2024,30(17):203-210.

JIA Zhenhua.Discussion About Diagnosis and Treatment Regularity of Infectious Lung Disease Epidemic and New Explanation of Lianhua Qingwen Formula[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(17):203-210.
贾振华.肺疫证治规律探讨与连花清瘟组方新解[J].中国实验方剂学杂志,2024,30(17):203-210. DOI： 10.13422/j.cnki.syfjx.20241247.

JIA Zhenhua.Discussion About Diagnosis and Treatment Regularity of Infectious Lung Disease Epidemic and New Explanation of Lianhua Qingwen Formula[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(17):203-210. DOI： 10.13422/j.cnki.syfjx.20241247.

摘要

病毒类呼吸系统传染病作为严重威胁人类健康的公共卫生事件，属“新病入络”范畴。笔者应用络病理论指导此类疾病防治，提出“肺疫”概念，揭示肺疫“气络-气道-血络”传变规律，提出“卫气同治、表里双解，先证用药、截断病势，整体调节、多靶治疗”积极干预治疗策略。通过系统梳理历代肺疫治疗用药规律，揭示“存正气”和“避毒气”防控总则，分析解毒、通下、芳化等治法应用规律，基于文献整理、数据挖掘、临床经验荟萃分析，传承创新制订中药连花清瘟组方。全方以银翘散、麻杏石甘汤为基础方加减化裁，汲取明代吴又可治疫病用大黄经验，再结合肺疫病变特点，创新加入红景天、广藿香，具有“清热与辛温兼备、解毒与芳化并用、扶正与通腑同施”组方特色，使清而不过凉，温而不助火，扶正不留邪，祛邪不伤正。同时，系列基础和临床研究证实，连花清瘟组方具有应对呼吸系统传染病的独特优势，揭示了肺络病证治理论指导肺疫防控的科学内涵。

Abstract

As a public health event that seriously threatens human health， viral respiratory infectious diseases fall within the scope of "new illness entering collaterals". Collateral disease theory is used to guide prevention and treatment of this type of diseases， thus to propose the concept of infectious lung disease epidemic and reveal its progress rule of "Qi collaterals-Qi pathway-blood collaterals". By analyzing main therapeutic methods including detoxication， precipitation draining and aromatization， this paper proposes active intervention and treatment strategy of "simultaneously treating Wei and Qi， relieving exterior-interior syndrome， using medicine with evidence， stopping the disease tendency， overall adjustment and multi-target therapy". Through systematic summarization of historical medication regularity in infectious lung disease epidemic， this paper demonstrates that "maintaining healthy Qi" and "avoiding harmful Qi" are the general rules of prevention and treatment. Based on literature review， data mining and meta analysis of clinical experiences， this study inherits and innovatively develops the formula of Chinese patent medicine Lianhua Qingwen. The formula is developed through a modification to basic formulae Yinqiaosan and Maxing Shigantang. It learns from Wu Youke's experience in treating epidemic diseases with Rhei Radix et Rhizoma， considers pathological characteristics of infectious lung disease epidemic， and innovatively adds Rhodiolae Crenulatae Radix et Rhizoma and Pogostemonis Herba. The new formula is featured by clearing heat， being warm-pungent， function of both detoxication and aromatization， as well as simultaneous implementation of strengthening the body resistance and purging Fu organs. It can clear heat but won't over cool the body， keep the body warm but won't contribute to pathogenic fire， strengthening the body resistance but won't retain pathogen， and eliminate pathogen but won't damage healthy Qi. Meanwhile， series of basic and clinical studies have demonstrated that Lianhua Qingwen formula has the unique advantages for respiratory infectious diseases， which reveals the scientific connotation of infectious lung disease prevention and control under the guidance of pulmonary collateral disease diagnosis and treatment theory.

关键词

肺络病证治肺疫传变规律新病入络连花清瘟方剂积极干预治疗策略

Keywords

diagnosis and treatment of collateral diseaselung epidemicprogress rulenew illness entering collateralsLianhua Qingwenformulasactive intervention treatment strategy

references

LU L，SU S，YANG H T ，et al.Antivirals with common targets against highly pathogenic viruses［J］.Cell，2021，184（6）：1604-1620.

WONG L R，PERLMAN S.Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses-are we our own worst enemy？［J］.Nat Rev Immunol，2022，22（1）：47-56.

李红蓉，吴以岭.络病研究的传承与创新［J］.南京中医药大学学报，2022，38（12）：1075-1085.

贾振华.连花清咳“化痰止咳”改善通气换气功能的科学内涵和临床价值解析［J］.中国实验方剂学杂志，2021，27（23）：190-194.

贾振华.络病理论指导新型冠状病毒肺炎证治探讨［J］.中国实验方剂学杂志，2020，26（12）：18-22.

张程程，王宁，罗光芝，等.吴有性应用大黄治疫探析［J］.中国中医基础医学杂志，2024，doi：10.19945/j.cnki.issn.1006-3250.20231130.003http://dx.doi.org/10.19945/j.cnki.issn.1006-3250.20231130.003.

贾振华.“外防内调”综合防控策略在呼吸系统公共卫生事件中的应用价值［J］.中国中西医结合杂志，2023，43（10）：1242-1246.

穆杰，冯全生，鲁法庭，等.论《伤寒论》“伤寒”本疫之说，参辨奥密克戎感染证治［J］.中华中医药学刊，2023，41（9）：27-29.

WANG D W，HU B，HU C，et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan，China［J］.JAMA，2020，323（11）：1061-1069.

MARTÍNEZ-SALAZAR B，HOLWERDA M，STÜDLE C，et al.COVID-19 and the vasculature：Current aspects and long-term consequences［J］.Front Cell Dev Biol，2022，10：824851.

CASTIGLIONE L，DROPPA M.Pulmonary hypertension and COVID-19［J］.Hamostaseologie，2022，42（4）：230-238.

WANG S，FENG Y M，ZHENG L，et al.Rosavin：Research advances in extraction and synthesis，pharmacological activities and therapeutic effects on diseases of the characteristic active ingredients of Rhodiola rosea L［J］.Molecules，2023，28（21）：7412.

LEI W，CHEN M H，HUANG Z F，et al.Salidroside protects pulmonary artery endothelial cells against hypoxia-induced apoptosis via the AhR/NF-κB and Nrf2/HO-1 pathways［J］.Phytomedicine，2024，128：155376.

朱舜亚，李晓萸，魏云玲，等.三种中药处方对SARS相关冠状病毒体外抑制作用的初步研究［J］.生物技术通讯，2003，14（5）：390-392.

LI R F，HOU Y L，HUANG J C，et al.Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus（SARS-CoV-2）［J］.Pharmacol Res，2020，156：104761.

尹玉洁，常丽萍.中药连花清瘟胶囊/颗粒在呼吸系统疾病中的药理研究及临床应用进展［J］.中国临床药理学与治疗学，2021，26（10）：1174-1180.

CHEN X F，WU Y L，CHEN C，et al.Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening［J］.Acta Pharm Sin B，2021，11（1）：222e236.

史利克，王悦，董星，等.连花清瘟联合美罗培南对耐药菌株的体外抑菌实验［J］.中华医院感染学杂志，2019，29（8）：1172-1175.

王艺竹.连花清瘟胶囊对呼吸道感染相关细菌生物膜的抑制作用研究及其遗传机制初探［D］.长春：吉林大学，2014.

雷洪涛，刘敏彦，欧阳竞锋，等.连花清瘟胶囊抗金黄色葡萄球菌生物膜研究［J］.中国实验方剂学杂志，2013，19（22）：161-164.

崔雯雯，金鑫，张彦芬，等.连花清瘟胶囊对脂多糖致急性肺损伤小鼠炎症因子和连接蛋白表达的影响［J］.中国药理学与毒理学杂志，2015，29（2）：213-219.

崔雯雯，金鑫，张彦芬，等.连花清瘟胶囊对脂多糖致急性肺损伤小鼠IKK/IκB/NF-κB信号通路的影响［J］.中成药，2015，37 （5）：953-958.

魏梅，宋煌勋，周红.连花清瘟胶囊辅治急性上呼吸道感染的疗效观察及其对IFN-γ的影响［J］.疑难病杂志，2014，13（4）：345-348.

赵明敬，赵晓琴，赵威.连花清瘟胶囊治疗急性上呼吸道感染的临床效果评价［J］.中华医院感染学杂志，2015，25（4）：839-841.

严明，谢雁鸣，孙梦华，等.基于Louvain聚类方法的连花清瘟胶囊治疗上呼吸道感染临床用药方案的复杂网络分析［J］.中国实验方剂学杂志，2021，27（15）：166-173.

DUAN Z P，JIA Z H，ZHANG J，et al.Natural herbal medicine Lianhua qingwen capsule anti-influenza A（H1N1） trial：A randomized，double blind，positive controlled clinical trial［J］.中华医学杂志：英文版，2011（18）：2925-2933.

刘更新，张艳霞，杨继清，等.连花清瘟胶囊治疗甲型H1N1流感随机对照临床研究［J］.疑难病杂志，2010，9（1）：14-16.

牛倩倩，陈愉，刘晔，等.连花清瘟胶囊治疗流行性感冒的有效性及安全性的系统评价［J］.中国中药杂志，2017，42（8）：1474-1481.

GONG X W，YUAN B Y，YUAN Y D，et al.Efficacy and safety of Lianhuaqingwen capsules for the prevention of coronavirus disease 2019：A prospective open-label controlled trial［J］.Evid Based Complement Alternat Med，2021，2021：7962630.

QIAN Y F，XU X L，ZHOU F F，et al.Effect of Lianhua Qingwen capsules on the positive rate of COVID-19 close contacts：A retrospective analysis of a large-scale population-based cohort study［J］.Phytomedicine，2023，112：154690.

ZHANG L，WU L，XU X L，et al.Effectiveness of Lianhua Qingwen capsule in treatment of asymptomatic COVID-19 patients：A randomized，controlled multicenter trial［J］.J Integr Complement Med，2022，28（11）：887-894.

ZHAN Y Q，CHEN R F，ZHENG Q S，et al.Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19（FLOSAN）：Protocol for a randomized，double-blind，international multicenter clinical trial［J］.J Thorac Dis，2023，15（5）：2859-2872.

HU K，GUAN W J，BI Y，et al.Efficacy and safety of Lianhuaqingwen capsules，a repurposed Chinese herb，in patients with coronavirus disease 2019：A multicenter，prospective，randomized controlled trial［J］.Phytomedicine，2021，85：153242.

HU C Y，HE B，GONG F F，et al.The adverse reactions of Lianhua Qingwen capsule/granule compared with conventional drug in clinical application：A Meta-analysis［J］.Front Pharmacol，2022，13：764774.

王艳勋，张科源，黄继汉，等.连花清瘟制剂临床应用的安全性评价［J］.中国医院用药评价与分析，2013，13（8）：676-681.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for TCM Intervention After Conventional Western Medicine Treatment for Stage Ⅰ-Ⅲ Colorectal Cancer

Visualized Analysis of Advances and Hot Spots of Lianhua Qingwen in Recent 10 Years

Complex Network Analysis of Lianhua Qingwen Capsule in Treatment of Upper Respiratory Tract Infection Based on Louvain Clustering

Construction of Tibetan Medicine Prescription Database for Treating "Gnyan-rims" and Analysis of Their Medication Law Based on Python Language

Data Mining of Caryophylli Fols-containing Formula and Analysis of Its Mechanism in Treatment of Diarrhea

Related Author

ZHANG Hongliang

HE Bin

LIU Jianping

SUN Hong

YANG Yufei

LI Minzhe

LI Pingping

LIU Likun

Related Institution

Xinjiang Uygur Autonomous Region Hospital of TCM

Xiyuan Hospital， Chinese Academy of Chinese Medical Sciences

Beijing University of Chinese Medicine

Beijing Cancer Hospital

Beijing Chaoyang Hospital，Capital Medical University

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰